Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downs
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... A custom-built, $2.5 million "split magnet" system with the potential ... made its debut at the National High Magnetic Field Laboratory ... at 25 tesla, easily besting the 17.5 tesla French record ... for early 20th-century inventor and engineer Nikola Tesla, is a ...
... as a preventative measure only achieve a short-term effect with ... up with even more aphids than untreated fields. This has ... of Wrzburg in the scientific journal PLoS One . ... triticale fields? This is what the biologists at the Department ...
... widely known PSA blood test for prostate cancer in men ... for breast cancer, the most common form of cancer in ... the ACS journal Analytical Chemistry . Chien Chou ... the test also is a potential biomarker of breast cancer ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Fewer aphids in organic crop fields 2
(Date:10/25/2014)... (PRWEB) October 25, 2014 Berkshire ... is pleased to announce the release of the ... highest level of contamination containment in critical processing ... 3 and higher cleanroom environments, ValuSeal® IonX™ is ... knit laundered wiper that continues Berkshire’s innovative focus ...
(Date:10/25/2014)... -- Research and Markets has announced the ... Research Area & by End User - Global Forecast ... In this report, the global epigenetics market is ... end users. The product segments of the epigenetics market ... kits, and reagents. The subsegments of the enzymes product ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... (OTC Bulletin Board: CHBT) (,China-Biotics", "the,Company"), a leading ... and distribution of probiotics products,today announced its financial ... year, ended June 30, 2008., First ... 19.5% year-over-year to $11.4 million -- Gross ...
... ... Aug. 14 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... science of healthy aging, today announced,financial results for the quarter ... June 30, 2008 was $691,000, compared with,$471,000 reported in the ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: